# Neurotrope

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurotrope

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.neurotropebioscience.com
- Total disclosed funding: $21M
- Latest round: Series A (Sep 5, 2013)
- Investors on record: 1

## About

Neurotrope, Inc. is a biotechnology company focused on developing innovative therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's disease, through cutting-edge research and advanced technologies.Neurotrope, Inc. specializes in developing therapies for neurodegenerative conditions. Founded in 2011, the company is headquartered in New York, US. The CEO is Alan Tuchman. In October 2013, Neurotrope raised USD 1.08 million in Series A funding, bringing the total amount raised to USD 1.08 million and achieving a current company valuation of USD 48.93 mn.Neurotrope offers a range of proprietary products designed to address neurodegenerative diseases. Its primary product line includes advanced therapeutic solutions focused on Alzheimer's disease, enhancing patient care through innovative drug development. The company markets its products in North America, Europe, and parts of Asia, targeting both small to mid-sized enterprises and larger corporations within the pharmaceutical and healthcare sectors.Neurotrope generates revenue primarily through a structured transactional model based on direct-to-consumer sales and partnerships with healthcare providers. Its pricing structure accommodates a variety of customer segments, ensuring that both individual patients and healthcare institutions can access its therapeutic solutions. Revenue is driven by consistent product sales and collaborations with strategic distributors.Neurotrope plans to launch new therapeutic products targeting Alzheimer’s and other neurodegenerative diseases in the coming years, with specific timelines yet to be disclosed. The company is actively exploring expansion into European and Asian markets by 2025 to broaden its reach. Funding from the recent Series A round will be utilized to support product development and market entry strategies, reinforcing the company's commitment to advancing innovative therapies.

## Funding rounds

- Series A, Sep 5, 2013, $12M — Intuitive Venture Partners
- Series A, Mar 12, 2013, $9.1M — Intuitive Venture Partners

## Investors

- Intuitive Venture Partners (https://capitalatlas.ai/funds/intuitive-venture-partners) — Series A